Humanized monoclonal antibody treatment in rheumatoid arthritis.
A 41-year-old woman with active, seropositive erosive rheumatoid arthritis was treated with the humanized monoclonal antibody Campath 1H. She had not responded or developed side effects to myocrisin, sulfasalazine and penicillamine, and had not responded to inpatient bedrest and physiotherapy. There was a rapid clinical improvement within 24 hours of infusion, which was maintained for about 12-14 weeks after the infusion. The lymphocyte count was suppressed for 7 months after treatment. There were no significant side effects during or after treatment. No anti-Campath 1H response was detected. This preliminary study suggests humanized monoclonal antibody therapy may be of value in the treatment of rheumatoid arthritis.
Kyle
V
V
Rheumatology Research Unit, Addenbrooke's Hospital, Cambridge, United Kingdom.
Roddy
J
J
Hale
G
G
Hazleman
B L
BL
Waldmann
H
H
D000203:Activities of Daily Living; D000328:Adult; D000818:Animals; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D015703:Antigens, CD / Q000276:immunology*; D000951:Antigens, Neoplasm; D001172:Arthritis, Rheumatoid / Q000503:physiopathology / Q000628:therapy*; D000074301:CD52 Antigen; D005260:Female; D006023:Glycoproteins; D006801:Humans; D010147:Pain Measurement; D051381:Rats
D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D000951:Antigens, Neoplasm; D000074301:CD52 Antigen; C000613862:CD52 protein, human; C000613864:Cd52 protein, rat; D006023:Glycoproteins